Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $59.90 Analyst target: $107.71 Upside: 79.82%
Arrowhead Pharmaceuticals, Inc. develops drugs for the treatment of intractable diseases in the United States. The company is headquartered in Pasadena, California.
See the full interactive analysis & chart →Informational only — not investment advice.